被忽视的热带疾病治疗市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球被忽视的热带疾病治疗市场价值为 37 亿美元，预计到 2034 年将以 4.6% 的复合年增长率增长，达到 58 亿美元。这一增长反映了全球对抗击被忽视的热带疾病 (NTD) 的日益关注，这种疾病仍然是低收入和发展中地区持续存在的健康挑战。被忽视的热带疾病是世界卫生组织确定的一组 20 种传染病，主要影响基本医疗保健有限的热带和亚热带地区的个体。这些疾病持续给医疗资源匮乏的社区带来巨大的负担，常常导致严重的发病率、长期残疾和死亡。

儘管多年来取得了进展，但被忽视的热带疾病仍然影响着全球超过十亿人，气候变迁、快速城市化和人口流动性增加进一步加速了其传播。卫生组织、政府和製药公司正在透过大规模药物管理计划、宣传活动和公私合作伙伴关係加强合作，以改善获得有效治疗方案的机会。诊断技术的进步、研究投入的增加以及解决热带感染中抗生素抗药性的需要进一步影响市场动态。随着全球医疗保健系统推动可持续和包容性的解决方案以遏制这些衰弱性疾病发病率的上升，对可靠的治疗干预的需求从未如此迫切。

被忽视的热带疾病治疗市场按疾病类型细分，其中登革热、狂犬病和沙眼是主要因素。 2024年，光是登革热领域就占据了全球市场份额的15%。登革热继续成为一个主要的健康问题，每年影响数亿人，并导致数万人死亡。过去五十年来，报告病例的数量急剧上升，这进一步表明有效治疗和预防策略的迫切需求。市场也致力于解决其他高负担疾病，如布鲁里溃疡、雅司病和恰加斯病，每种疾病都带来了独特的治疗挑战并增加了全球医疗负担。

神经管缺陷的治疗方案大致分为药物和疫苗。 2024年，药品部门创造了27亿美元的收入。抗寄生虫、抗真菌和抗生素药物仍然是治疗这些疾病的第一线工具，在降低感染率和改善弱势群体预后的公共卫生策略中发挥关键作用。

受部分地区被忽视的热带病患病率上升以及政府和慈善机构的积极支持推动，美国被忽视的热带疾病治疗市场规模到 2024 年将达到 13.3 亿美元。美国国立卫生研究院等组织正与全球卫生机构联手扩大治疗管道并推动创新。

全球市场的主要参与者包括拜耳、安斯泰来製药和卫材，它们在神经管缺陷药物和疫苗开发方面处于领先地位。这些公司优先考虑研发，与卫生组织和政府结盟，致力于为受影响的社区提供可负担的、可扩展的解决方案。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 被忽视的热带疾病发病率不断上升
    • 有利的政府倡议
    • 提高对被忽视的热带疾病的认识
  • 产业陷阱与挑战
    • 缺乏医疗基础设施
• 成长潜力分析
• 监管格局
• 技术格局
• 未来市场趋势
• 差距分析
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：依疾病类型，2021 年至 2034 年

• 主要趋势
• 登革热
• 狂犬病
• 沙眼
• 布鲁里溃疡
• 雅司病
• 麻风
• 恰加斯病
• 非洲人类锥虫病（昏睡病）
• 利甚曼病
• 土源性蠕虫病
• 其他疾病类型

第六章：市场估计与预测：依治疗类型，2021 年至 2034 年

• 主要趋势
• 药物
  • 抗寄生虫
  • 抗真菌
  • 抗生素
  • 其他药物
• 疫苗

第七章：市场估计与预测：依管理路线，2021 年至 2034 年

• 主要趋势
• 口服
• 注射剂

第八章：市场估计与预测：按配销通路，2021 年至 2034 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第九章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋

第十章：公司简介

• Astellas Pharma
• Bayer
• Bharat Biotech
• Eisai
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Novartis
• Pfizer
• Sanofi
• Takeda Pharmaceutical
• Tarsus Pharmaceuticals

The Global Neglected Tropical Disease Treatment Market was valued at USD 3.7 billion in 2024 and is estimated to grow at a CAGR of 4.6% to reach USD 5.8 billion by 2034. This growth reflects the increasing global focus on combating neglected tropical diseases (NTDs), which remain a persistent health challenge across low-income and developing regions. NTDs refer to a group of 20 communicable diseases identified by the World Health Organization that mainly affect individuals in tropical and subtropical regions with limited access to essential healthcare. These diseases continue to place an immense burden on underserved communities, often leading to significant morbidity, long-term disability, and mortality.

Despite years of progress, NTDs still impact more than a billion people worldwide, with climate change, rapid urbanization, and increased human mobility further accelerating their spread. Health organizations, governments, and pharmaceutical companies are stepping up collaborative efforts through mass drug administration programs, awareness campaigns, and public-private partnerships to improve access to effective treatment options. Market dynamics are further influenced by advancements in diagnostics, growing investments in research, and the need to address antimicrobial resistance in tropical infections. The demand for reliable therapeutic interventions has never been more urgent as healthcare systems around the globe push for sustainable and inclusive solutions to curb the rising incidence of these debilitating diseases.

The Neglected Tropical Disease Treatment Market is segmented by disease type, with dengue, rabies, and trachoma among the top contributors. In 2024, the dengue segment alone accounted for 15% of the global market share. Dengue continues to emerge as a major health concern, affecting hundreds of millions every year and resulting in tens of thousands of deaths. The number of reported cases has seen a dramatic rise over the last five decades, reinforcing the critical need for effective treatments and prevention strategies. The market also addresses other high-burden conditions such as Buruli ulcer, yaws, and Chagas disease, each presenting unique treatment challenges and adding to the global healthcare load.

Treatment options for NTDs are broadly classified into drugs and vaccines. In 2024, the drug segment generated USD 2.7 billion in revenue. Anti-parasitic, antifungal, and antibiotic medications continue to be frontline tools in managing these diseases, playing a pivotal role in public health strategies to reduce infection rates and improve outcomes in vulnerable populations.

The U.S. Neglected Tropical Disease Treatment Market reached USD 1.33 billion in 2024, driven by increasing NTD prevalence in select regions and active support from government and philanthropic institutions. Organizations like the NIH are joining forces with global health bodies to expand treatment access and drive innovation.

Key players in the global market include Bayer, Astellas Pharma, and Eisai, which are leading innovations in drug and vaccine development for NTDs. These companies are prioritizing R&D, forming alliances with health organizations and governments, and aiming to deliver affordable, scalable solutions for affected communities.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of neglected tropical diseases
    • 3.2.1.2 Favorable government initiatives
    • 3.2.1.3 Growing awareness of neglected tropical diseases
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Lack of healthcare infrastructure
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter’s analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Dengue
• 5.3 Rabies
• 5.4 Trachoma
• 5.5 Buruli ulcer
• 5.6 Yaws
• 5.7 Leprosy
• 5.8 Chagas disease
• 5.9 Human African trypanosomiasis (sleeping sickness)
• 5.10 Leishmaniases
• 5.11 Soil-transmitted helminthiases
• 5.12 Other disease types

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Drugs
  • 6.2.1 Anti-parasite
  • 6.2.2 Antifungal
  • 6.2.3 Antibiotics
  • 6.2.4 Other drugs
• 6.3 Vaccines

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Astellas Pharma
• 10.2 Bayer
• 10.3 Bharat Biotech
• 10.4 Eisai
• 10.5 Gilead Sciences
• 10.6 GlaxoSmithKline
• 10.7 Johnson & Johnson
• 10.8 Merck
• 10.9 Novartis
• 10.10 Pfizer
• 10.11 Sanofi
• 10.12 Takeda Pharmaceutical
• 10.13 Tarsus Pharmaceuticals